Relates to Crystalline forms of hydrochloride of (R) - 7 - chlorine - N - (3 - quinuclidin - il) benzo [b] thiophene-2-carboxamide Monohydrate such as: (a) a Crystal Form I is characterized by a pattern of x-ray Powder diffraction Peaks which are expressed as 2tetha 4.50, 9.04, 14.60, 15.14, 15.8 0, 16.60, 18.16, 18.44, 19.48, 21.74 and 2.79 (0.20 degrees when measured against a pattern of domestic Silicon and (b) a Crystalline Form II is characterized by a pattern of x-ray Powder diffraction Peaks which are expressed as 2tetha 13.58, 4.48, 9, 14, 1648, 7.02, 1944, 22.46 and 25.00 + 0.20 degrees when measured against a Pat Ron Silicon internal.It also refers to a synthesis procedure and a Pharmaceutical composition. This Compound is an agonist of alpha 7 nicotinic receptor useful in the treatment of attention deficit disorder, Parkinsons disease, Alzheimers disease, SchizophreniaSE REFIERE A FORMAS CRISTALINAS DEL CLORHIDRATO DE (R)-7-CLORO-N-(QUINUCLIDIN-3-IL)BENZO[b]TIOFENO-2-CARBOXAMIDA MONOHIDRATADO TALES COMO: A) UNA FORMA CRISTALINA I CARACTERIZADA POR UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE TIENE PICOS EXPRESADOS COMO 2TETHA DE 4.50, 9.04, 14.60, 15.14, 15.80, 16.60, 18.16, 18.44, 19.48, 21.74 Y 25.46 ± 0.20 GRADOS CUANDO SE MIDE CONTRA UN PATRON DE SILICIO INTERNO Y B) UNA FORMA CRISTALINA II CARACTERIZADA POR UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE TIENE PICOS EXPRESADOS COMO 2TETHA DE 4.48, 9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 Y 25.00 ± 0.20 GRADOS CUANDO SE MIDE CONTRA UN PATRON DE SILICIO INTERNO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE SINTESIS Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN AGONISTA DEL RECEPTOR NICOTINICO ALFA 7 UTIL EN EL TRATAMIENTO DE TRASTORNO POR DEFICIT DE ATENCION, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA
